Surveillance of protein expression patterns on malignant cell surfaces has yielded a notable observation with potential implications for immunotherapy development. Researchers at the University of California San Francisco (UCSF) have identified the oncogenic protein Src on the exterior surface of cancer cells, a location where it does not appear under normal physiological conditions. The findings, published in the journal Science in March 2026, may advance efforts to identify reliable immunotherapy targets for solid tumors, a category of malignancy that has historically resisted many forms of immune-based intervention.

The discovery originated not through deliberate hypothesis-driven screening but through incidental observation during routine examination of surface protein profiles on malignant cells. Jim Wells, a biologist at UCSF, observed Src present on the cell surface during his research into cancer cell surface proteomics. Under normal circumstances, Src functions exclusively as an intracellular kinase, confined within the cytoplasm where it participates in signal transduction cascades that regulate cell proliferation and survival. Its presence on the outer membrane of cancer cells was not anticipated.

The research team subsequently confirmed that Src surface expression was observed on malignant cells and was absent from healthy donor tissue examined in the study. This differential expression profile is precisely the characteristic that immunotherapy developers seek when evaluating potential therapeutic targets. An ideal target must be present on tumor cells in sufficient density and distribution to permit immune recognition, while remaining absent or minimally expressed on normal tissue to avoid autoimmune toxicity.

The Challenge of Solid Tumor Immunotherapy

To contextualize this finding within the broader oncological treatment framework, it is necessary to review the current state of immunotherapy for solid tumors. Immune checkpoint inhibitors and adoptive cell therapies, including chimeric antigen receptor (CAR) T-cell therapies, have produced durable responses in hematologic malignancies and select solid tumors. However, the majority of solid tumor types continue to respond poorly to immunotherapeutic approaches.

Several factors contribute to this resistance. Solid tumors frequently create immunosuppressive microenvironments that attenuate T-cell function. Physical barriers within the tumor stroma limit immune cell infiltration. Perhaps most consequentially, identifying surface antigens that are both tumor-specific and uniformly expressed across the heterogeneous cell populations within a given solid tumor has proven considerably more difficult than initially anticipated.

The antigens targeted by many existing CAR T-cell therapies are shared between malignant and normal tissues. This shared expression profile creates dose-limiting toxicity concerns that constrain therapeutic windows. Researchers have sought tumor-associated antigens with restricted normal tissue expression for decades, and the list of validated candidates with favorable safety profiles remains limited relative to the breadth of solid tumor types requiring treatment.

Surface Display of Intracellular Proteins

The biological mechanism by which Src arrives at the cell surface warrants examination. Src is a proto-oncogene product and a non-receptor tyrosine kinase. Mutations and overexpression of Src are associated with multiple malignancies, including colorectal, breast, pancreatic, and lung cancers. Its canonical function is intracellular, where it phosphorylates downstream substrates to activate pathways including Ras-MAPK and PI3K-Akt, promoting tumor cell survival, invasion, and metastatic potential.

The transport of intracellular proteins to the outer leaflet of the plasma membrane is a recognized but incompletely understood phenomenon in cancer biology. One proposed mechanism involves exosome-mediated or vesicular trafficking processes that, under pathological conditions, relocalize proteins from their normal intracellular compartments to the cell surface. Colloquially, researchers in the Wells laboratory have described this process as cancer cells “barfing” proteins onto their surface, a descriptor that captures the apparently disordered nature of the relocalization rather than a regulated secretory pathway.

This surface translocation is not unique to Src. Other intracellular proteins, including heat shock proteins and certain metabolic enzymes, have been documented on the surfaces of stressed or malignant cells. The significance of the Src finding lies in the oncogenic relevance of the protein and the specificity of its surface expression for malignant versus normal cells, at least within the tissue samples examined in the current study.

Assessment from External Researchers

Kathleen Yates, a biologist at the Broad Institute of MIT and Harvard University who was not involved in the study, offered a measured assessment of the findings. The observation of Src kinase presented on the cancer cell surface was described as notable, and the research team was credited with considerable accomplishment. Yates simultaneously cautioned that the translational significance of targeting cell-surface Src remains an open question. Whether this observation will ultimately yield clinical benefit requires further investigation that the current study does not yet provide.

This calibrated response reflects standard scientific practice when evaluating early-stage mechanistic findings. The pathway from identifying a surface-expressed protein on malignant cells in a laboratory setting to demonstrating that therapeutic targeting of that protein produces meaningful clinical outcomes in patients is lengthy and subject to numerous failure points. Preclinical validation in animal models, characterization of antigen density and distribution across diverse tumor types, assessment of antigen loss variants that may permit immune escape, and evaluation of potential on-target off-tumor toxicity in normal tissues must each be addressed before clinical translation becomes feasible.

Implications for Immunotherapy Target Discovery

If surface expression of Src is confirmed across a broad range of solid tumor types and in primary patient-derived specimens rather than only cell lines or limited tissue samples, the implications for immunotherapy development would be considerable. CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates each require a cell-surface target accessible to large-molecule biologics or immune effector cells. Src, given its intracellular localization in normal tissue, would in principle satisfy a critical requirement that many currently evaluated targets do not.

The discovery also raises a more fundamental question about the prevalence of intracellular oncoproteins on the cancer cell surface. If Src can be relocalized under malignant conditions, other intracellular drivers of oncogenesis may exhibit similar surface translocation. The cancer proteome contains numerous high-value oncogenic targets, including mutant KRAS, p53, and MYC, that have resisted direct pharmacological inhibition for decades partly because of the difficulty of targeting intracellular proteins with conventional biologics. Surface expression, even partial or heterogeneous, would make these proteins newly accessible to immune-based approaches.

Systematic profiling of the cancer cell surface proteome, sometimes termed the surfaceome, has expanded considerably as mass spectrometry-based methodologies and proximity labeling techniques have improved. The UCSF finding demonstrates that surfaceome analyses may continue to reveal unexpected candidates that would not have been nominated through transcriptomic or genomic screening alone, since neither approach would have predicted surface localization from a protein with no transmembrane domain or conventional secretory signal.

Population-Level Context for Solid Tumor Burden

The public health relevance of advances in solid tumor immunotherapy is substantial. Solid tumors, which include carcinomas of the lung, colorectum, breast, prostate, and pancreas, account for the overwhelming majority of cancer-related mortality in the United States and globally. The National Cancer Institute estimated that approximately 1.96 million new cancer diagnoses would be recorded in the United States in 2025, with solid tumors comprising the preponderant share of that incidence. Five-year survival rates for metastatic solid tumors, which represent the patient population most in need of novel therapeutic approaches, remain low across most histological types despite incremental improvements in systemic therapy over the preceding decade.

Hawaii-specific cancer surveillance data from the Hawaii Department of Health and the University of Hawaii Cancer Center document incidence patterns that, while reflecting unique demographic and environmental characteristics of the state population, are broadly consistent with national trends. Lung, colorectal, and breast cancers represent leading contributors to cancer mortality among Hawaii residents. Any advancement in solid tumor immunotherapy efficacy would therefore carry direct relevance to the patient populations served by Hawaii’s medical institutions.

Next Steps in Research

The immediate research priorities following the Science publication will likely include validation of Src surface expression in larger and more diverse tumor specimen collections, mechanistic characterization of the trafficking pathway responsible for surface relocalization, and preclinical evaluation of Src-directed immunotherapeutic constructs in relevant tumor models. Identification of the precise molecular form of Src presented on the cell surface, whether it retains full kinase activity and whether its surface-exposed epitopes are accessible and immunogenic, will be required before target selection for therapeutic development can proceed.

Regulatory and translational research infrastructure for advancing novel immunotherapy targets has expanded within academic medical centers and biotechnology companies over the past decade, which may accelerate the timeline from basic discovery to early-phase clinical evaluation relative to historical norms. Nonetheless, the distance between a serendipitous laboratory observation and an approved therapeutic is substantial, and the field has accumulated considerable experience with promising targets that did not survive rigorous clinical testing.

The Wells laboratory finding contributes a potentially valuable data point to the ongoing effort to expand the repertoire of actionable solid tumor antigens. Its ultimate contribution to oncology will depend on whether subsequent investigation